Acer Therapeutics Inc. - FORM 10-Q - EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - November 13, 2017

Attached files

file filename
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Acer Therapeutics Inc.acer_ex311.htm
EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - Acer Therapeutics Inc.acer_ex322.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - Acer Therapeutics Inc.acer_ex312.htm
EX-4.1 - SPECIMEN COMMON STOCK CERTIFICATE - Acer Therapeutics Inc.acer_ex41.htm
10-Q - QUARTERLY REPORT - Acer Therapeutics Inc.acer_10q.htm
 
EXHIBIT 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report of Acer Therapeutics Inc. (the “Company”) on Form 10-Q for the period ending September 30, 2017 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, Chris Schelling, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
 
1. 
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
2. 
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
Date: November 13, 2017  
 
By:
/s/ Chris Schelling 
 
 
 
Chris Schelling 
President and Chief Executive Officer
(Principal Executive Officer)
 
 
 

Acer Therapeutics Inc. Reports